

Bibliography Report

May 1st 2009 – May 31st 2009

Page 1 of 2

Bagatell R, Wagner LM, Cohn S, Maris JM, Reynolds CP, Stewart CF, Voss SD, Gelfand M, Kretschmar CS, London W. Irinotecan plus temozolomide in children with recurrent or refractory neuroblastoma: A phase II Children's Oncology Group study. *J Clin Oncol*; 27(15S):10011, 2009. ANBL0421; Neuroblastoma Disease Committee; Abstract. COG # 9694

Barr F, Duan F, Smith LM, Gustafson D, Pitts M, Hammond S, Gastier-Foster JM. [Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group](#). *Genes Chromosomes Cancer*; (ePub ahead of print), 2009. **PMC Journal - In Process**.
Soft Tissue Sarcoma Committee; Research Paper. COG # 9544

Berg S, Russell HV, Cairo M, Ingle AM, Blaney S, Adamson P. Phase I trial and pharmacokinetic (PK) of lenalidomide (LEN) in pediatric patients with relapsed/refractory solid tumors or myelodysplastic syndrome (MDS): A Children's Oncology Group Phase 1 Consortium study. *J Clin Oncol*; 27(15S):10023, 2009. ADVL0013, ADVL0319; Developmental Therapeutics Scientific Committee; Abstract. COG # 9543

Bleyer WA, Friedman S, Finnegan S, Montello M, Budd T, Anderson B, Trimble EL. Association of adolescent and young adult cancer treatment trial activity with a national mortality reduction benefit in the United States. *J Clin Oncol*; 27(15S):6605, 2009. Cancer Control and Survivorship Scientific Committee; Abstract. COG # 9696

Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, Mosse YP, Kim C, Diskin SJ, Cole KA, Bosse K, Diamond M, Laudenslager M, Winter CL, Bradfield JP, Scott R, Jagannathan J, Garris M, McConville C, London W, Seeger R, Grant SF, Li H, Rahman N, Rappaport E, Hakonarson H, Maris JM. [Common variations in BARD1 influence susceptibility to high-risk neuroblastoma](#). *Nat Genet*; (Epub ahead of print), 2009. **PMC In Process**.
ANBL06B1; Neuroblastoma Disease Committee; Research Paper. COG # 9619

Devidas M. [Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis](#). *Br J Haematol*; 145(3):376-88, 2009. **PMC Journal - In Process**.
Acute Lymphoblastic Leukemia Disease Committee; Research Paper. COG # 9635

Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, Marina N, Leavey P, Gebhardt M, Healey J, Shamberger RC, Goorin A, Miser J, Meyer J, Arndt CA, Sailer S, Marcus K, Perlman E, Dickman P, Grier H. [Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study](#). *J Clin Oncol*; 27(15):2536-2541, 2009. **PMC Journal - In process**.
7942; Bone Sarcoma Disease Committee, Diagnostic Imaging Discipline Committee; Research Paper. COG # 9392

Gumy-Pause F, Ozsahin HA, Khoshbeen-Boudal M, Pardo B, Betts D, Maillet P, Sappino A. ATM gene analysis in neuroblastoma: A report from the COG. *J Clin Oncol*; 27(15S):10058, 2009. ANBL07B1; Neuroblastoma Disease Committee; Abstract. COG # 9697

Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson RS, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, Hunger S, Sallan SE, Look AT. [High frequency of PTEN, PI3K and AKT abnormalities in T cell acute lymphoblastic leukemia](#). *Blood*; (ePub ahead of print), 2009. **PMC Journal - In Process**.
9404; Acute Lymphoblastic Leukemia Disease Committee; Research Paper. COG # 9661

Malempati S, Weigel BJ, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Fox F, Voss SD, Adamson PC, Blaney S. A Phase I Trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase 1 Consortium study. *J Clin Oncol*; 27(15S):10013, 2009.

ADVL0712; Developmental Therapeutics Scientific Committee; Abstract. COG # 9632

Malogolowkin M, Krailo M, Frazier L, Olson TA. Study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high-risk germ cell tumors: A Children's Oncology Group report. *J Clin Oncol*; 27(15S):10035, 2009.

Acute Lymphoblastic Leukemia Disease Committee; Abstract. COG # 9695

McCarten KM, Rosen NS, Friedman D, Schwartz C, Voss SD, FitzGerald TJ. Feasibility of Real Time Diagnostic Imaging Central Review in Multicenter Cancer Trials. *AJR Am J Roentgenol*; 192(5S):A21, #076, 2009.

AHOD0031; Diagnostic Imaging Discipline Committee, Hodgkin Lymphoma Committee; Abstract. COG # 9483

Ognjanovic S, Puumala SE, Spector LG, Smith FO, Robison L, Olshan A, Ross JA. [Maternal health conditions during pregnancy and acute leukemia in children with Down syndrome: A Children's Oncology Group study](#). *Pediatr Blood Cancer*; 52(5):602-8, 2009. **PMCID: PMC2659730**.

AE23; Epidemiology Scientific Committee ; Research Paper. COG # 9326

Wagner LM, Perentesis J, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney S, Adamson PC. Phase I Trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase 1 Consortium Study. *J Clin Oncol*; 27(15S):10017, 2009.

ADVL0414; Developmental Therapeutics Scientific Committee; Abstract. COG # 9633

Widemann B, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, Bender JG, Stempak D, Balis F, Blaney S. Phase I Study of Sorafenib in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I consortium Trial. *J Clin Oncol*; 27(15S):10012, 2009.

ADVL0413; Developmental Therapeutics Scientific Committee; Abstract. COG # 9634

Yu A, Gilman A, Ozkaynak F, London W, Kreissman S, Chen HR, Matthay KK, Cohn S, Maris JM, Sondel P. A phase III randomized trial of chimeric anti-GD2 antibody + GM-CSF + IL2 immunotherapy of high-risk neuroblastoma in first response: Children's Oncology Group (COG) study ANBL0032. *J Clin Oncol*; 27(15S):1006z, 2009.

ANBL0032; Neuroblastoma Disease Committee; Abstract. COG # 9644